Secondary Logo

Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment


doi: 10.1097/MLR.0000000000001083

In the April 2017 issue of Medical Care, Figure 2 of the article by Wen et al was mislabeled. The label of the y-axis should be “$ Million Buprenorphine Spending.”

Back to Top | Article Outline


1. Wen H, Hockenberry JM, Borders TF, et al. Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment. Med Care. 2017;55:336–341.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.